Browse by author
Lookup NU author(s): Professor Ruth Plummer
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Background: The hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor shrinkage in more than 90% of patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC in the BCC Outcomes with LDE225 Treatment study.Objective: This report provides long-term follow-up data collected up to 12 months after the last patient was randomized.Methods: In this multicenter, randomized, double-blind phase II study, patients were randomized 1: 2 to sonidegib 200 or 800 mg. The primary end point was objective response rate assessed by central review.Results: Objective response rates in the 200- and 800-mg arms were 57.6% and 43.8% in locally advanced BCC and 7.7% and 17.4% in metastatic BCC, respectively. Among the 94 patients with locally advanced BCC who responded, only 18 progressed or died and more than 50% had responses lasting longer than 6 months. In addition, 4 of 5 responders with metastatic BCC maintained an objective response. Grade 3/4 adverse events and those leading to discontinuation were less frequent with sonidegib 200 versus 800 mg (38.0% vs 59.3%; 27.8% vs 37.3%, respectively).Limitations: No placebo or comparator arms were used because sonidegib demonstrated efficacy in advanced BCC in a phase I study, and the hedgehog pathway inhibitor vismodegib was not yet approved.Conclusion: With longer follow-up, sonidegib demonstrated sustained tumor responses in patients with advanced BCC.
Author(s): Dummer R, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Gogov S, Pallaud C, Yi TT, Mone M, Chang ALS, Cornelis F, Kudchadkar R, Trefzer U, Lear JT, Sellami D, Migden MR
Publication type: Article
Publication status: Published
Journal: Journal of the American Academy of Dermatology
Print publication date: 01/07/2016
Online publication date: 07/04/2016
Acceptance date: 22/02/2016
ISSN (print): 0190-9622
ISSN (electronic): 1097-6787
Publisher: Mosby, Inc.
Altmetrics provided by Altmetric